CIPLA Financial Statement Analysis
|
||
|
The Revenues of CIPLA have increased by 13.28% YoY .
The Earnings Per Share (EPS) of CIPLA has increased by 27.89 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
CIPLA Last 5 Annual Financial Results
[BOM: 500087|NSE : CIPLA]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹25,774 Cr | ₹22,753 Cr | ₹21,763 Cr | ₹19,160 Cr | ₹17,132 Cr |
| Expenses | ₹19,483 Cr | ₹17,763 Cr | ₹17,251 Cr | ₹14,911 Cr | ₹13,951 Cr |
| Operating Profit (Excl OI) | ₹6,291 Cr | ₹4,990 Cr | ₹4,512 Cr | ₹4,249 Cr | ₹3,181 Cr |
| Other Income | ₹747 Cr | ₹512 Cr | ₹322 Cr | ₹270 Cr | ₹369 Cr |
| Interest | ₹90 Cr | ₹110 Cr | ₹106 Cr | ₹161 Cr | ₹197 Cr |
| Depreciation | ₹1,051 Cr | ₹1,172 Cr | ₹1,052 Cr | ₹1,068 Cr | ₹1,175 Cr |
| Profit Before Tax | ₹5,702 Cr | ₹4,038 Cr | ₹3,493 Cr | ₹3,290 Cr | ₹2,178 Cr |
| Profit After Tax | ₹4,155 Cr | ₹2,835 Cr | ₹2,559 Cr | ₹2,401 Cr | ₹1,547 Cr |
| Consolidated Net Profit | ₹4,122 Cr | ₹2,802 Cr | ₹2,517 Cr | ₹2,405 Cr | ₹1,547 Cr |
| Earnings Per Share (Rs) | ₹65.29 | ₹51.05 | ₹34.71 | ₹31.19 | ₹29.82 |
| PAT Margin (%) | 14.29 | 11.73 | 9.17 | 8.61 | 8.51 |
| ROE(%) | 18.34 | 16.63 | 12.85 | 13.10 | 14.13 |
| ROCE(%) | 23.64 | 22.77 | 18.19 | 17.24 | 17.85 |
| Total Debt/Equity(x) | 0.00 | 0.01 | 0.02 | 0.04 | 0.10 |
Key Financials |
||
| Market Cap | : | ₹ 121,195.4 Cr |
| Revenue (TTM) | : | ₹ 27,547.6 Cr |
| Net Profit(TTM) | : | ₹ 5,291.1 Cr |
| EPS (TTM) | : | ₹ 65.5 |
| P/E (TTM) | : | 22.9 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| CIPLA | -1.7% | 2.3% | -5.8% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.3% | -3.3% | 8.3% |
| DIVIS LABORATORIES | -1.5% | 0.8% | 42.3% |
| TORRENT PHARMACEUTICALS | -3.3% | -1.4% | 9.8% |
| DR REDDYS LABORATORIES | -1.6% | 8.4% | 10.6% |
| MANKIND PHARMA | -3.3% | -6.1% | 3.4% |
| ZYDUS LIFESCIENCES | -1.8% | 5.9% | -12% |
| LUPIN | -3.2% | -1.1% | 22.1% |
| AUROBINDO PHARMA | -4.2% | -7.8% | -12.7% |
CIPLA Revenues
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 13.28 % |
| 5 Yr CAGR | 10.75 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹25,774 Cr | 13.28 | |
| Mar2024 | ₹22,753 Cr | 4.55 | |
| Mar2023 | ₹21,763 Cr | 13.59 | |
| Mar2022 | ₹19,160 Cr | 11.84 | |
| Mar2021 | ₹17,132 Cr | - | |
CIPLA Operating Profit
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 26.07 % |
| 5 Yr CAGR | 18.59 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹6,291 Cr | 26.07 | |
| Mar2024 | ₹4,990 Cr | 10.60 | |
| Mar2023 | ₹4,512 Cr | 6.20 | |
| Mar2022 | ₹4,249 Cr | 33.57 | |
| Mar2021 | ₹3,181 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 11.31 % |
| 5 Yr CAGR | 7.08 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 24.41% | 11.31 | |
| Mar2024 | 21.93% | 5.79 | |
| Mar2023 | 20.73% | -6.54 | |
| Mar2022 | 22.18% | 19.44 | |
| Mar2021 | 18.57% | - | |
CIPLA Profit After Tax
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 47.10 % |
| 5 Yr CAGR | 27.77 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹4,122 Cr | 47.10 | |
| Mar2024 | ₹2,802 Cr | 11.33 | |
| Mar2023 | ₹2,517 Cr | 4.65 | |
| Mar2022 | ₹2,405 Cr | 55.50 | |
| Mar2021 | ₹1,547 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 21.82 % |
| 5 Yr CAGR | 13.83 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 14.29 % | 21.82 | |
| Mar2024 | 11.73 % | 27.92 | |
| Mar2023 | 9.17 % | 6.50 | |
| Mar2022 | 8.61 % | 1.18 | |
| Mar2021 | 8.51 % | - | |
CIPLA Earnings Per Share (EPS)
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 27.89 % |
| 5 Yr CAGR | 21.64 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹65 | 27.89 | |
| Mar2024 | ₹51 | 47.08 | |
| Mar2023 | ₹35 | 11.29 | |
| Mar2022 | ₹31 | 4.59 | |
| Mar2021 | ₹30 | - | |
CIPLA Return on Capital Employed (ROCE)
[BOM: 500087|NSE : CIPLA]
| Y-o-Y | 3.82 % |
| 5 Yr CAGR | 7.28 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 23.64% | 3.82 | |
| Mar2024 | 22.77% | 25.18 | |
| Mar2023 | 18.19% | 5.51 | |
| Mar2022 | 17.24% | -3.42 | |
| Mar2021 | 17.85% | - | |
CIPLA Share Price vs Sensex
| Current Share Price | : | ₹1,500.5 |
| Current MarketCap | : | ₹ 121,195.4 Cr |
| Updated EOD on | : | Jun 20,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | -1.7% |
2.3% |
-5.8% |
| SENSEX | 1.6% |
1% |
7% |
CIPLA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE 100 ESG INDEX | 1.7% | 1.3% | 7.4% |
| BSE SENSEX 50 | 1.5% | 1.1% | 6.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 50 | 1.6% | 1.2% | 7% |
| NIFTY GROWTH SECTORS 15 | 1.5% | 0.9% | 3.6% |
| NIFTY100 ESG SECTOR LEADERS | 1.3% | 0.9% | 7.1% |
| NIFTY 100 | 1.3% | 0.9% | 4.4% |
| NIFTY50 EQUAL WEIGHT | 1.2% | 1.2% | 4.7% |
You may also like the below Video Courses
FAQ about CIPLA Financials
How the annual revenues of CIPLA have changed ?
The Revenues of CIPLA have increased by 13.28% YoY .
How the Earnings per Share (EPS) of CIPLA have changed?
The Earnings Per Share (EPS) of CIPLA has increased by 27.89 % YoY .
Check out Intrinsic Value of Peers of CIPLA
Compare Stock Analytics of Peers of CIPLA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
